Literature DB >> 15269295

Association of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors.

Eva Wardelmann1, Aksana Hrychyk, Sabine Merkelbach-Bruse, Katharina Pauls, Jennifer Goldstein, Peter Hohenberger, Inge Losen, Christoph Manegold, Reinhard Büttner, Torsten Pietsch.   

Abstract

Most gastrointestinal stromal tumors (GISTs) carry activating mutations of the KIT gene encoding the receptor tyrosine kinase KIT. In a previous study we were able to show an association between the lack of KIT mutations (wild-type GISTs) and the presence of a significant epithelioid tumor component. A very recent study described the occurrence of PDGFRalpha mutations in KIT wt GISTS. Therefore, we studied a panel of 87 GISTs for mutations in the hot spot regions of the PDGFRalpha gene with single strand conformation polymorphism analysis and sequencing and correlated the PDGFRalpha status with pathomorphological data. We detected 20 cases with exon 18 mutations but none with exon 12 mutations. The mutations were located in the second kinase domain of PDGFRalpha with 16 point mutations, and four larger deletions of 9 to 12 bp. All cases with mutations in the PDGFRalpha gene revealed wild-type KIT in common regions of mutation, ie, exons 9 and 11. Most interestingly, the occurrence of PDGFRalpha mutations was significantly associated with a higher frequency of epithelioid or mixed morphology (18 of 20 cases, P < 0.0001) and gastric location (all cases, P = 0.0008). Our data indicate that GISTs represent distinctive entities, differing in genetic, biological, and morphological features.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15269295      PMCID: PMC1867629          DOI: 10.1016/s1525-1578(10)60510-7

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  17 in total

1.  KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.

Authors:  B P Rubin; S Singer; C Tsao; A Duensing; M L Lux; R Ruiz; M K Hibbard; C J Chen; S Xiao; D A Tuveson; G D Demetri; C D Fletcher; J A Fletcher
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

Review 2.  Gastrointestinal stromal tumors: recent advances in understanding of their biology.

Authors:  M Miettinen; M Sarlomo-Rikala; J Lasota
Journal:  Hum Pathol       Date:  1999-10       Impact factor: 3.466

3.  c-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant.

Authors:  Eva Wardelmann; Iris Neidt; Erhard Bierhoff; Nicola Speidel; Christoph Manegold; Hans-Peter Fischer; Ulrich Pfeifer; Torsten Pietsch
Journal:  Mod Pathol       Date:  2002-02       Impact factor: 7.842

4.  Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors.

Authors:  M Taniguchi; T Nishida; S Hirota; K Isozaki; T Ito; T Nomura; H Matsuda; Y Kitamura
Journal:  Cancer Res       Date:  1999-09-01       Impact factor: 12.701

5.  Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.

Authors:  A T van Oosterom; I Judson; J Verweij; S Stroobants; E Donato di Paola; S Dimitrijevic; M Martens; A Webb; R Sciot; M Van Glabbeke; S Silberman; O S Nielsen
Journal:  Lancet       Date:  2001-10-27       Impact factor: 79.321

6.  Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors.

Authors:  Eva Wardelmann; Inge Losen; Volkmar Hans; Iris Neidt; Nicola Speidel; Erhard Bierhoff; Thomas Heinicke; Torsten Pietsch; Reinhard Büttner; Sabine Merkelbach-Bruse
Journal:  Int J Cancer       Date:  2003-10-10       Impact factor: 7.396

Review 7.  Diagnosis of gastrointestinal stromal tumors: A consensus approach.

Authors:  Christopher D M Fletcher; Jules J Berman; Christopher Corless; Fred Gorstein; Jerzy Lasota; B Jack Longley; Markku Miettinen; Timothy J O'Leary; Helen Remotti; Brian P Rubin; Barry Shmookler; Leslie H Sobin; Sharon W Weiss
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

Review 8.  Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review.

Authors:  Markku Miettinen; Wa'el El-Rifai; Leslie H L Sobin; Jerzy Lasota
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

9.  Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.

Authors:  Seiichi Hirota; Akiko Ohashi; Toshirou Nishida; Koji Isozaki; Kazuo Kinoshita; Yasuhisa Shinomura; Yukihiko Kitamura
Journal:  Gastroenterology       Date:  2003-09       Impact factor: 22.682

10.  PDGFRA activating mutations in gastrointestinal stromal tumors.

Authors:  Michael C Heinrich; Christopher L Corless; Anette Duensing; Laura McGreevey; Chang-Jie Chen; Nora Joseph; Samuel Singer; Diana J Griffith; Andrea Haley; Ajia Town; George D Demetri; Christopher D M Fletcher; Jonathan A Fletcher
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

View more
  42 in total

1.  [Are sarcoma centers needed in Germany? Experience gained with the Bonner GIST register].

Authors:  E Wardelmann; S Merkelbach-Bruse; H U Schildhaus; R Büttner
Journal:  Pathologe       Date:  2011-02       Impact factor: 1.011

2.  Sporadic Cajal cell hyperplasia is common in resection specimens for distal oesophageal carcinoma. A retrospective review of 77 consecutive surgical resection specimens.

Authors:  Abbas Agaimy; Peter H Wünsch
Journal:  Virchows Arch       Date:  2005-11-25       Impact factor: 4.064

3.  Gonadoblastoma: evidence for a stepwise progression to dysgerminoma in a dysgenetic ovary.

Authors:  Katharina Pauls; Folker E Franke; Reinhard Büttner; Hui Zhou
Journal:  Virchows Arch       Date:  2005-06-21       Impact factor: 4.064

4.  Improved detection of KIT exon 11 duplications in formalin-fixed, paraffin-embedded gastrointestinal stromal tumors.

Authors:  Jerzy Lasota; Bartosz Wasag; Sonja E Steigen; Janusz Limon; Markku Miettinen
Journal:  J Mol Diagn       Date:  2007-02       Impact factor: 5.568

5.  Chromosome copy number changes carry prognostic information independent of KIT/PDGFRA point mutations in gastrointestinal stromal tumors.

Authors:  Mara Silva; Isabel Veiga; Franclim R Ribeiro; Joana Vieira; Carla Pinto; Manuela Pinheiro; Bárbara Mesquita; Catarina Santos; Marta Soares; José Dinis; Lúcio Santos; Paula Lopes; Mariana Afonso; Carlos Lopes; Manuel R Teixeira
Journal:  BMC Med       Date:  2010-05-14       Impact factor: 8.775

Review 6.  [Inflammatory fibroid polyp: from Vanek's "submucosal granuloma" to the concept of submucosal mesenchymal neoplasia].

Authors:  H-U Schildhaus; S Merkelbach-Bruse; E Binot; R Büttner; E Wardelmann
Journal:  Pathologe       Date:  2010-03       Impact factor: 1.011

7.  Value of epithelioid morphology and PDGFRA immunostaining pattern for prediction of PDGFRA mutated genotype in gastrointestinal stromal tumors (GISTs).

Authors:  Abbas Agaimy; Claudia Otto; Alexander Braun; Helene Geddert; Inga-Marie Schaefer; Florian Haller
Journal:  Int J Clin Exp Pathol       Date:  2013-08-15

8.  Molecular spectrum of c-KIT and PDGFRA gene mutations in gastro intestinal stromal tumor: determination of frequency, distribution pattern and identification of novel mutations in Indian patients.

Authors:  Firoz Ahmad; Purnima Lad; Simi Bhatia; Bibhu Ranjan Das
Journal:  Med Oncol       Date:  2014-12-07       Impact factor: 3.064

9.  Gastrointestinal stromal tumors with pseudocystic change mimicking a pancreatic tumor: two case reports.

Authors:  Ursula Pauser; Sebastian Hinz; Hartmut Merz; Alfred C Feller
Journal:  J Med Case Rep       Date:  2009-05-07

Review 10.  Genetic aberrations of gastrointestinal stromal tumors.

Authors:  Jilong Yang; Xiaoling Du; Alexander J F Lazar; Raphael Pollock; Kelly Hunt; Kexin Chen; Xishan Hao; Jonathan Trent; Wei Zhang
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.